Further, RdB/shVEGF-, RdB/IL12-, or RdB/IL12/shVEGF-treated tumors exhibited significantly lower levels of VEGF (242.5 ± 22.5, 320.6 ± 8.0, or 212.0 ± 15.7, pg/mL, respectively; **P < 0.01) than control RdB tumors (Figure 3B, 796.3 ± 6.7 pg/mL), implying that both IL12 and shVEGF can efficiently suppress VEGF expression in the tumor milieu. Here, VEGFA is linked to neoplasm.